PGHD is characterized by insufficient production of growth hormone (GH) by the pituitary gland, which is a small gland located at the base of the brain. It is estimated that 1 in 4,000-10,000 children globally have PGHD.

Here are 7 things children with PGHD may experience:

Short stature
Delayed puberty
Bone development challenges
Decreasing muscle mass and weakness
Emotional challenges
Low blood sugar
Reduced strength and endurance
Left untreated, PGHD can limit a child’s potential, physically, emotionally, and socially.

PGHD doesn’t just affect children—parents and caregivers of children with PGHD may feel discouraged and overwhelmed during this journey. Their concerns and fears about how this condition will impact their child can leave them feeling unheard.

It’s critical for parents to consult a healthcare professional as soon as they begin to notice delays in their child’s growth. Early diagnosis of PGHD and treatment are time-sensitive, especially because a child’s growth plates will eventually fuse, limiting their ability to achieve their full height potential. Delaying treatment can negatively impact final adult height and potentially affect other aspects of development.

For decades, the only treatment option available was daily injections of human growth hormone (somatropin). Long-acting growth hormone treatments have been developed that are given just once a week.

Healthcare professionals can work with parents to determine if treatment is needed and help ease concerns such as:

Noticing growth concerns and seeking guidance
Feeling anxious about timely diagnosis before growth plates fuse
Uncertainty about options to treat PGHD
Navigating the responsibilities of PGHD management
On Wednesday, September 17, Dr. Nidhi Gupta, pediatric endocrinologist, and founder and CEO of KAP Pediatric Endocrinology, is available to share her insights on what all parents need to know about PGHD. She will also discuss its signs and symptoms, and how treatment can help.

Interview courtesy: Ascendis Pharma

#AscendisPharma #GrowthAwarenessWeek #ChildsOverallHealth #PGHD #DiagnosingPediatricGrowthHormone

The post IS MY CHILD’S GROWTH ON TRACK? What Parents Should Know September 14-20: Children’s Growth Awareness Week appeared first on Good News!.

And that’s exactly what they’ve done. After researching potential treatment options Jordan and his family decided to enroll him into a clinical trial for a new treatment for patients with Duchenne muscular dystrophy. The family had so much hope that this could help their son.

Now, Jordan and his family are celebrating the success he’s had in the clinical trial for the treatment which was received Accelerated Approval by the FDA for Duchenne patients who have a specific mutation like Jordan. His mom says it’s been incredible to watch all the positive changes he’s been experiencing, during the four years since he’s been receiving the treatment. Jordan who is now 12-years old, says he tries to make every day the best day ever.

Jordan is one of an estimated 10,000 boys in the U.S. with this rare disease. Early signs of Duchenne include delayed ability to sit, stand or walk. Patients face increasing loss of mobility and by adolescence many require the use of a wheelchair. In teenage years patients begin experiencing problems with heart and lung function that leads to serious, life-threatening complications.

Laura McLinn talks about her son Jordan’s journey and how she and her family approach every day and never gave up hope. She’ll also discuss how she has become an advocate for helping others with Duchenne muscular dystrophy and will offer advice to other parents about options available that can help.

Interview courtesy: NS Pharma

#laura #mclinn #dreams #jordan #duchenne #muscular #dystrophy #disease #muscles #family #journey #treatment #clinical #hope #fda #mutation #positive #change #approach #ns #pharma

The post A REMARKABLE MOTHER FIGHTING FOR HER SON TO LIVE HIS BEST LIFE INSPIRES & HELPS OTHERS WITH A PROGRESSIVE RARE MUSCLE DISEASE appeared first on Good News!.

More than 34 million Americans – just over 1 in 10 – have diabetes, and neuropathic pain associated with diabetic peripheral neuropathy of the feet, or more commonly referred to as diabetic nerve pain, is one of its most common complications.

The painful symptoms associated with this nerve damage include numbness, tingling, as well as burning, shooting or stabbing sensations that most often affect the lower extremities.

It is a progressive and debilitating complication of diabetes that will affect approximately more than 5 million Americans in 2021 and is expected to double by 2030.

Lindsay Colbert, Executive Director of The Foundation for Peripheral Neuropathy, and Dr. Rodica Pop-Busui, MD, PhD, Professor of Internal Medicine, Metabolism, Endocrinology and Diabetes and Vice Chair Clinical Research, Department of Internal Medicine at the University of Michigan, Ann Arbor will be available to talk about the findings from a new national survey of patients that captured beliefs, perspectives and attitudes towards their diabetic nerve pain.

A key finding from the survey revealed an overwhelming 71% of patients desire change, and are seeking better treatments and a future with less pain. Furthermore, over a third of respondents reported needing to rest more; the most frequently reported necessary life-style change due to their pain.

Key Facts and Figures:

The lack of effective, innovative treatment options have left many patients with a significant unmet medical need

Two in five patients had to visit three or more doctors before getting the right diagnosis for their pain

58% of patients are not satisfied with the current treatment plan for their diabetic nerve foot pain

Interview is courtesy of Averitas Pharma, Inc.

https://www.averitaspharma.com/
https://www.nervepainandme.com/

#lindsay #colbert #rodica #pop #busui #phd #md #neuropathy #foundation #painful #symptoms #neuropathic #pain #diabetic #nerve #numbness #averitas #pharma #medical #medicine #pop-busui #me #patients

The post Diabetic Nerve Pain will Affect Approximately 5 Million Americans in 2021 appeared first on Good News!.

Find Out More About this Condition. Capsian Patch, … can be considered. a specific approved product is Qutinza
More than 34 million Americans – just over 1 in 10 – have diabetes1, and neuropathic pain associated with diabetic peripheral neuropathy of the feet, or more commonly referred to as diabetic nerve pain, is one of its most common complications.2
The painful symptoms associated with this nerve damage include numbness, tingling, as well as shooting or stabbing sensations that most often affect the lower extremities.3
Itis a progressive and debilitating complication of diabetes that will affect approximately more than 5 million Americans in 20204 and is expected to double by 2030.5
Joining us now to discuss neuropathic pain associated with diabetic peripheral neuropathy – or diabetic nerve pain – and this newly approved treatment option is Dr. David Simpson, Professor of Neurology at the Icahn School of Medicine at Mount Sinai in New York City.
Key Facts and Figures:
• The lack of effective, innovative treatment options has left many patients with a significant unmet medical need.
• The condition is more common in patients with type 2 diabetes and increases with age and duration of disease.
When you book a window, we’ll provide you with guest bio & suggested questions. The interview is courtesy of Averitas Pharma, Inc.
References:
1. CDC Division of Diabetes Translation, National Diabetes Statistics Report, 2020. https://www.cdc.gov/diabetes/library/features/diabetes-stat-report.html#:~:text=New%20in%202020%2C%20the%20report,1%20in%203%E2%80%94have%20prediabetes. Accessed July 6, 2020
2. University of Chicago Center for Peripheral Neuropathy. Types of peripheral Neuropathy. http://peripheralneuropathycenter.uchicago.edu/learnaboutpn/typesofpn/diabetes/diabetes.shtml. Accessed July 6,2020
3. American Diabetes Association. Peripheral NeuorapthyOverview. https://www.diabetes.org/diabetes/complications/neuropathy/peripheral-neuropathy.Accessed July 17, 2020
4. LTP2020-2030: ADDRESSABLE POPULATIONS BY CONDITION (PDPN, PSNP, PHN, CINP).Company data on file. April 30, 2020.
5. Gore, M., Brandenburg, N. A., Dukes, E., Hoffman, D. L.,Tai, K.-S., & Stacey, B. (2005). Pain Severity in Diabetic Peripheral Neuropathy is Associated with patient Functioning, Symptom Levels of Anxiety and Depression, and Sleep. Journal of Pain and Symptom Management, 30(4),374-385. doi:10.1016/j.jpainsymman.2005.04.009.
https://www.cdc.gov/media/releases/2017/p0718-diabetes-report.html
6. CDC,Behavioral Risk Factor Surveillance System, 2018
7. America’sHealth Rankings. United Health Foundation.https://www.americashealthrankings.org/explore/annual/measure/Diabetes. Accessed July 13, 2020

The post DIABETIC NERVE PAIN WILL AFFECT APPROXIMATELY 5 MILLION AMERICANS IN 2020 appeared first on Good News!.